---
title: Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release
  Syndrome in Haploidentical Transplantation
date: '2024-11-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39576962/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241125170911&v=2.18.0.post9+e462414
source: Blood
description: Haploidentical hematopoietic cell transplantation (haplo-HCT) is an increasingly
  used treatment for hematologic malignancies. Although post-transplant cyclophosphamide
  (PtCy) has improved graft vs. host disease (GvHD) prophylaxis in haplo-HCT, patients
  continue to experience life-threatening complications. IFN-γ and IL-6 are central
  in the pathophysiology of GvHD and cytokine release syndrome (CRS), and both cytokines
  signal through Janus kinase (JAK)-1. We tested the effect of adding the ...
disable_comments: true
---
Haploidentical hematopoietic cell transplantation (haplo-HCT) is an increasingly used treatment for hematologic malignancies. Although post-transplant cyclophosphamide (PtCy) has improved graft vs. host disease (GvHD) prophylaxis in haplo-HCT, patients continue to experience life-threatening complications. IFN-γ and IL-6 are central in the pathophysiology of GvHD and cytokine release syndrome (CRS), and both cytokines signal through Janus kinase (JAK)-1. We tested the effect of adding the ...